Extracorporeal liver support in severe alcoholic hepatitis by Parés Darnaculleta, Albert & Mas, Antoni
Albert Parés, Antoni Mas, Liver Unit, Hospital Clínic, Univer-
sity of Barcelona, IDIBAPS, CIBERehd, 08036 Barcelona, Spain
Author contributions: Parés A and Mas A reviewed and pub-
lished data on therapy of alcoholic hepatitis and the effects of 
extracorporeal liver support in these patients, performed previous 
studies with this therapy, and wrote the manuscript.
Correspondence to: Albert Parés, MD, Liver Unit, Hospital 
Clínic, University of Barcelona, IDIBAPS, CIBERehd, C/ Villar-
roel 170, 08036 Barcelona, Spain. pares@ub.edu
Telephone: +34-93-2275753   Fax: +34-93-2271779
Received: November 1, 2013  Revised: February 27, 2014
Accepted: April 28, 2014
Published online: July 7, 2014
Abstract
The severity of alcoholic hepatitis (AH) which may co-
exist with cirrhosis varies greatly, from asymptomatic 
forms which are detected in alcoholic patients without 
any sign of liver disease, except laboratory abnormali-
ties, to severe forms characterised by deep jaundice, 
ascites, hepatic encephalopathy and low prothrombin 
index. In hospitalized patients the mortality could be 
as high as 75%. The elevated number of therapeutic 
proposals reported for more than forty years reveals 
the lack of efficacy of a particular modality. Even in the 
most favorable trials, the survival is already very poor 
and in some cases related to the development of renal 
failure or hepatorenal syndrome. There are some moti-
vating reports concerning albumin dialysis as a support 
treatment in patients with severe AH, either alone or in 
combination with other pharmacological therapies. The 
favorable effects of albumin dialysis in patients with 
severe AH suggest that the procedure used alone or 
in combination with other therapies may have a role in 
this clinical condition. This will be particularly relevant 
to offer an alternative therapy in these patients, thus 
being a potential bridge to recovery or to be listed for 
liver transplantation.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: The elevated number of proposals reported 
for more than forty years reveals the lack of efficacy of 
a particular therapeutic modality for severe alcoholic 
hepatitis. This review summarizes data regarding the 
favorable effects of extracorporeal liver support, par-
ticularly with respect to the improvement of systemic 
hemodynamics, hepatic encephalopathy and renal 
function, thus sustaining that the procedure used alone 
or in combination with pharmacological therapies may 
have a role in this clinical condition.
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ALCOHOLIC HEPATITIS
Alcoholic hepatitis (AH) is a clinical condition charac-
terised by hepatocellular injury with associated inflam-
mation, necrosis and varied extent of  fatty changes and 
fibrosis, particularly prominent in the zone 3 of  the he-
patic acinus[1]. The lesion typically shows focally intense 
lobular infiltration with polymorphonuclear leukocytes, 
although periportal mononuclear inflammation also oc-
curs. Some injured hepatocytes contain eosinophilic and 
fibrillar material resulting from condensated cytoskeletal 
intermediary filaments. The extent of  fibrosis varies in 
AH, but usually collagen is placed in a typical pericellular 
and perivenular distribution, resulting in a pattern of  in-
terstitial fibrosis[2].
AH may be observed alone, but may coexist with 
liver cirrhosis[3,4]. As a single lesion it is considered pre-
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cirrhotic, since a high percentage of  patients who con-
tinue drinking alcohol eventually develop cirrhosis[5]. The 
severity of  AH varies greatly, from asymptomatic forms 
which are detected in alcoholic patients without any sign 
of  liver disease[6], except laboratory abnormalities, to se-
vere forms of  liver damage characterised by intense jaun-
dice, ascites, hepatic encephalopathy and low prothromin 
index[7]. In hospitalized patients the mortality rate ranges 
from 5% to 25% in most series; however mortality could 
be much higher when the patient has severe liver failure 
with deep jaundice and hepatic encephalopathy as well as 
low prothrombin index. In these AH subjects mortality 
could be as high as 75%, but is generally around 50%[3,4,7,8]. 
Actually, the variables associated with low survival are 
bilirubin, prothrombin time and the presence of  hepatic 
encephalopathy, ascites, renal failure and concomitant bac-
terial infection[7]. In this concern, Maddrey et al[9] described 
a score for establishing the severity of  AH. Since then, 
other scores have been proposed, all including bilirubin, 
and most of  them with prothrombin time, renal function 
and the presence of  hepatic encephalopathy as the main 
components (Table 1)[7,9-12]. The purpose of  these scor-
ing systems is to estimate the short-term survival, and to 
determine if  the patient should be treated with specific 
treatments, mainly corticosteroids. The Lille’s group has 
described another score, which defines whether cortico-
steroid therapy should be stopped after a week, or contin-
ued for 28 d[13].
STANDARD TREATMENT OF ALCOHOLIC 
HEPATITIS
Stop drinking alcohol is the unique therapy that constant-
ly improves the outcome of  AH[1,3-5]. Therefore, measures 
addressed at establishing and maintaining abstinence are 
critical for the management of  these patients, although 
some patients can progress to cirrhosis even remaining 
abstinent[5].
The development of  specific treatments for AH has 
been difficult by a poor understanding of  its pathogen-
esis. A number of  treatments have been proposed, in-
cluding corticosteroids, enteral or parenteral nutrition and 
other agents that are able to modify the hypermetabolic 
state as propylthiouracil, or decreasing fibrosis such as 
colchicine or d-penicillamine[1,3,4]. Different antioxidants 
and hepatoprotective agents, as well as hepatotropic 
agents have also been used. More recently, some results 
have been published concerning the effect of  pentoxifyl-
line, anti-tumor necrosis factor alpha (TNFa) antibodies, 
and N-acetyl cysteine. 
Despite the lack of  consistent results, recent analysis 
and the conclusions of  the most well performed studies 
advocate for the use of  corticosteroids in patients with 
AH and severe liver failure[9,13-17]. The AASLD guidelines 
recommends for a four week course of  prednisolone 
(40 mg/d for 28 d, typically followed by discontinuation 
or a 2-wk taper) in patients without contraindications 
to steroid use, and a Maddrey’s score above 32[3]. The 
EASL guidelines also consider corticosteroid therapy 
with the same approach, but with the use of  the different 
prognostic scores and with early identification of  non-re-
sponders to corticosteroids to limit unnecessary exposure 
to complications[2]. 
Pentoxifylline, a nonselective phosphodiesterase in-
hibitor that increases intracellular concentrations of  ad-
enosine monophosphate and guanosine monophosphate 
and ultimately inhibits TNFa production, has been evalu-
ated in AH. In the prospective, randomized, double-blind 
clinical trial in patients with severe disease, pentoxifylline 
resulted in better survival, mainly because improvement 
of  hepatorenal syndrome[18]. Certainly, no effects of  pent-
oxifylline were observed on liver function and changes in 
cytokines. In the largest randomized controlled trial of  
270 patients with severe AH assessing the combination 
of  prednisolone and pentoxifylline failed to show any 
benefit over corticosteroids alone[19], but still pentoxifyl-
line therapy (400 mg orally 3 times daily for 4 wk) could 
be considered, especially if  there are contraindications 
to steroid therapy, since apparently the drug reduces the 
risk of  hepatorenal syndrome and has some potential in 
decreasing short-term mortality because of  renal failure. 
Nutritional supplementation provided via oral or 
enteral routes has been also assessed in patients with se-
vere AH. In summary, dietary supplementation improves 
nutritional status and nitrogen balance without signifi-
cant side effects in these patients. Moreover, nutritional 
supplementation improves liver function tests more 
rapidly than standard treatment but no definite results 
were reported concerning survival improvement[20,21]. On 
the other hand, a randomized controlled trial comparing 
enteral nutrition versus corticosteroids did not show any 
difference in 28-d mortality rate[21]. Nevertheless, deaths 
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Table 1  Prognostic factor in severe alcoholic hepatitis according to different scores
Ref. Score N Bilirubin PT/INR Creatinine/
renal failure
Leukocytes/
infection
HE Age Albumin Bilirubin 
change day 7
Parés et al[7] 1978 NN1  1051 Yes Yes Yes Yes Yes No No No
Maddrey et al[9] 1978 Maddrey2,3      552,3 Yes Yes No No No No No No
Dunn et al[11] 2005 MELD3    733 Yes Yes Yes No No No No No
Forrest et al[10] 2005 GAHS2  2412 Yes Yes Yes yes No Yes No No
Louvet et al[13] 2007 Lille2,3 295 Yes Yes Yes No No Yes Yes Yes
Dominguez et al[12] 2008 ABIC1,3 103 Yes Yes Yes No No Yes Yes No
1Histologic diagnosis; 2Clinical diagnosis; 3Treated with corticosteroids; NN: No name.
occurred earlier with enteral nutrition while treatment 
with corticosteroids was associated with higher mortality 
in the weeks following the treatment period.
Anti-TNFa agents have also been assessed in pa-
tients with severe AH with promising results reagard-
ing to the improvement of  the indices of  liver failure. 
However, development of  severe infections is the main 
inconvenient for using such treatment in these patients, 
who are already prone to develop very important adverse 
events[22-24]. N-acetylcysteine is an antioxidant agent that 
replenishes the hepatocyte glutathione stores, with clear 
favorable effect in patients with acute liver failure. The in-
travenous administration for 14 d to patients with severe 
AH diagnosed with liver biopsy had no significant impact 
on 1-or 6-mo survival in patients receiving enough nu-
tritional support, but more recently, it has been reported 
that patients treated with combination therapy (cortico-
steroids and N-acetylcysteine) had better 1-mo survival 
than patients treated with corticosteroids alone[25].
The elevated number of  proposals reported for more 
than forty years reveals the lack of  efficacy of  a particular 
modality. Even in the most favorable trials, the survival is 
still very poor and in some cases related to the develop-
ment of  renal failure or hepatorenal syndrome. There 
are some motivating reports concerning albumin dialysis 
as a support treatment in patients with severe AH, either 
alone or in combination with other pharmacological 
treatments.
EXTRACORPOREAL LIVER SUPPORT
In recent years significant advances have been achieved in 
the treatment of  the complications of  liver disease, but, 
in general, there is no definitive method for improving 
short and long-term outcomes. The only treatment that 
has shown real efficacy is liver transplantation, which no-
tably increases the rate of  survival in patients with fulmi-
nant hepatitis[26] as well as in those with end-stage chronic 
liver disease, mainly with cirrhosis[27]. It is, therefore, rea-
sonable to attempt to find therapeutic methods which are 
able, albeit transitorily, to maintain patients with severe 
decompensated liver disease in a situation which will al-
low them to undergo liver transplantation or to recover 
and avoid transplantation.
New extracorporeal liver support systems have ap-
peared based on the use of  complex procedures using 
liver cells integrated into the system[28,29]. These devices, 
known as bioartificial livers, consist of  biologic compo-
nents (pig hepatocytes freshly isolated, human hepato-
blastoma cell lines or human hepatocytes obtained from 
cadaveric livers not useful for liver transplantation) in a 
synthetic framework. In the extracorporeal bioreactor, 
the blood of  the patient with liver failure is in close con-
tact with the cultured cells through an ex vivo perfusion 
system. Since these devices include liver cells, they theo-
retically have both the ability to synthesize and remove 
toxic substances. Some results show that the procedure 
may be useful in patients with acute liver failure, particu-
larly when it is due to paracetamol poisoning[30]. Despite 
great efforts, no clear effects have been proved using 
these complicated devices, which additionally are very ex-
pensive and with many issues to be answered before the 
utilization in the clinical setting. 
These biological or bio-hybrid systems are extremely 
complex and hardly available in clinical practice. By con-
trast, the nonbiological systems are essentially based on 
existing technologies such as hemodialysis, hemofiltra-
tion and adsorption[31,32], and can thus be more feasible 
to integrate in the routine management of  patients with 
severe acute or chronic liver failure (Table 2). Three dif-
ferent nonbiological artificial liver support systems are 
currently available, on the adsorbent and binding capacity 
of  circulating albumin, in addition to high volume plas-
mapheresis: (1) single pass albumin dialysis consists on 
a continuous renal replacement therapy device, in which 
the blood of  the patient is dialyzed, through a high flux 
dialyzer, against an albumin-containing dialyzate, allow-
ing the removal of  small molecules and water-soluble 
toxins[33]; (2) molecular adsorbent recirculating system 
(MARS) combines hemodialysis against albumin solution, 
with a conventional dialysis or hemofiltration method. 
The procedure consists of  a hollow fiber dialysis module 
in which the blood of  the patient is dialyzed across a 
high-flux polysulfone membrane impregnated with albu-
min, while maintaining a constant flow of  albumin-rich 
dialysate (20% albumin) in the extracapillary compart-
ment[34]. The circulating toxins from the blood of  the 
patients are adsorbed in the binding sites on the mem-
brane, and hence pass to the free albumin-binding sites 
in the dialysate. The albumin dialysate is then cleansed 
by standard dialysis or filtration and by the sequentially 
perfusion over two columns (an activated charcoal and an 
anion exchange resin column which removes the toxins 
bound to albumin), in order to regenerate the albumin 
solution. Since the pore size of  the membrane is 50 KD, 
larger substances and the albumin from the patient are 
not removed; and (3) fractionated plasma separation 
and adsorption (FPSA) system uses a plasma separation 
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Table 2  Extracorporeal liver support systems
Plasma exchange and Albumin dialysis Bioartificial
HepatAssist
Plasma exchange (PE) Extracorporeal liver assist device (ELAD)
Single pass albumin dialysis (SPAD) Modular extracorporeal liver support (MELS)
Molecular adsorbent recirculating system (MARS) Bioartificial liver support system (BLSS)
Fractionated plasma separation and adsorption (PROMETHEUS) Amsterdam Medical Center-bioartificial liver (AMC-BAL)
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and renal function, which ameliorated in all the patients 
according to the circulating creatinine levels[36]. In a sub-
sequent analysis, the same group also reported a sharp 
decrease in portal pressure with MARS, effect that was 
persistent for up to 18 h after finishing the therapy[37]. 
Favorable effects of  albumin dialysis on decreasing portal 
pressure were also shown in four patients with acute-on-
chronic liver failure[38]. 
Favorable effects on liver function tests and systemic 
hemodynamics were also reported in alcoholic patients 
with acute decompensation who were treated with MARS 
or FPSA, and compared with a group managed with 
standard medical therapy. Bilirubin and bile acids levels, 
which are relevant albumin bound toxins, decreased after 
both MARS and FPSA[39]. Moreover, improvement in the 
mean arterial pressure, stroke volume and systemic vas-
cular resistance index (SVRI) was only observed in the 6 
patients treated with MARS, but not in those treated with 
FPSA. These different consequences of  the two thera-
peutic procedures were associated with significant de-
creases of  vasoactive hormones in patients under MARS 
with no changes in patients treated with FPSA. 
In our center, the effects of  albumin dialysis on sys-
temic hemodynamics and vasoactive agents were evalu-
ated in 29 MARS treatments performed in 10 patients 
(seven males, age: 48.4 ± 2.0 years) with clinical and 
histologic diagnosis of  severe AH defined by a total 
bilirubin higher than 10 mg/dL, and prothrombin index 
lower than 50%. The mean MELD score was 26 (range: 
20-42). Standard hematological and liver function tests, 
systemic hemodynamics and vasoactive agents such as 
plasma renin activity (PRA), angiotensin Ⅱ and the cata-
bolic products of  nitric oxide (NOx) were determined 
before and after each treatment. Current infection or 
upper gastrointestinal bleeding were excluded in these 
patients[40]. In addition to the favorable and significant 
effects on decreasing serum bilirubin (Figure 1), MARS 
therapy was associated with increases in the mean arte-
rial pressure (MAP) and SVRI. These circulatory effects 
resulted in significant decreases in PRA, angiotensin Ⅱ 
and NOx. MAP increased in 21 MARS sessions (group Ⅰ) 
and decreased in 8 (group Ⅱ). PRA, angiotensin Ⅱ and 
NOx decreased predominantly in patients from group Ⅰ, 
which were those with a significantly lower leukocyte 
count at baseline. At baseline no other differences were 
observed between the two groups. Apart from a decrease 
of  PRA, a significant drop in circulating renin concentra-
tion after the MARS treatment was also observed (from 
195 ± 35 to 110 ± 29 pg/mL, P = 0.01), with very low 
concentrations of  this hormone in the dialyzate (11 ± 3 
pg/mL). Contrarily, no changes in TNFa concentration 
were observed after treatment (from 84 ± 11 to 84 ± 9 
pg/mL, P = NS), while high amounts of  this cytokine 
were identified in the albumin dialyzate (195 ± 3 pg/mL) 
(Figure 2). This can be explained by the permanent re-
lease of  TNFa as a consequence of  the systemic inflam-
matory response. We concluded that albumin dialysis 
using MARS results in prominent changes in systemic 
technique combined with adsorption. It consists on a 
membrane with a pore size of  250 kDa, which lets the 
separation of  blood cells and large proteins from plasma. 
The albumin with the bound toxins is filtered through 
the membrane and passes over an absorber with a neu-
tral resin and after that to an anion exchanger. Both the 
filtered plasma and blood are afterwards combined and 
dialyzed to remove water-soluble toxins[35].
MANAGEMENT OF SEVERE ALCOHOLIC 
HEPATITIS WITH EXTRACORPOREAL 
LIVER SUPPORT
Extracorporeal liver support procedures, which have the 
ability to remove some potential damaging circulating 
molecules may, therefore, have a role in patients with se-
vere AH, either alone or in combination with other treat-
ments. This is particularly relevant taking into account 
that despite the best favorable effects of  corticosteroids 
in recent clinical trials, there is already a short-term sur-
vival rate in this condition. Since now, not many patients 
with AH have been treated with this procedure. In one 
study 8 patients with severe acute AH and a precipitat-
ing decompensation event (mainly upper gastrointestinal 
bleeding or severe infection) on a background of  alcohol-
ic cirrhosis, MARS therapy was associated with improved 
liver biochemical abnormalities, systemic haemodynam-
ics, renal function and encephalopathy. Actually, there 
was a marked reduction in the bilirubin level following 
the first treatments, which then remained stable and did 
not return to the baseline level even after stopping MARS 
therapy. Hepatic synthetic function also improved, since 
there was a significant decrease of  prothrombin time 
(INR), as well as a recovery from hepatic encephalopathy 
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Figure 1  Changes in circulating levels of total bilirubin and plasma renin 
activity before and after each 7-h molecular adsorbent recirculating sys-
tem session performed on 10 patients with severe alcoholic hepatitis (gray 
shaded bars). Ten days later there was a recovery of these levels although 
they were lower than before treatment (P = NS). aP < 0.05 vs before and after 
each molecular adsorbent recirculating system (MARS) session.
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hemodynamics, which in turn are associated with clear 
decreases in vasoactive substances. These changes may 
partially explain the positive effects of  this therapy in pa-
tients with AH and severe liver failure. 
Besides the hemodynamic effects, albumin dialysis 
resulted in a marked effect on hepatic encephalopathy 
as well[41]. Actually, in these patients eight episodes of  
encephalopathy were recorded before MARS. Albumin 
dialysis resulted in a considerable decrease in the degree 
of  hepatic encephalopathy. Moreover, no encephalopa-
thy was present after treatment in 5 of  the 8 episodes. 
Improvement of  hepatic encephalopathy was associated 
with clear attenuations in serum bilirubin and a significant 
raise in albumin concentration, along with clear recover-
ies in creatinine and electrolyte concentrations. Moreover, 
total amino acid, phenolic aromatic amino acid concen-
trations and tryptophan levels were significantly greater 
in patients with AH than in patients with pruritus and 
normal liver function who served as controls. Baseline 
branched amino acid between the two groups of  patients 
were similar, but the Fischer ratio was appreciably lower 
in patients with AH. Circulating ammonia levels were 
higher in patients with AH than in controls. 
Total amino acid concentrations decreased signifi-
cantly in patients with AH and no changes were ob-
served in the control subjects. Branched amino acids in 
sera were not changed by MARS, but phenolic aromatic 
amino acids decreased markedly in patients with AH and 
increased in the control patients with pruritus. Therefore, 
the Fischer ratio increased in patients with severe AH 
(17%) but decreased in controls with resistant pruritus 
(3%). These changes were more prominent after correc-
tion by the baseline albumin levels. No relevant changes 
were observed in either the serum levels of  tryptophan 
or ammonia. Patients with baseline hepatic encephalopa-
thy and albumin concentration below 24 g/L, and those 
in whom albumin dialysis resulted in a decrease in total 
bilirubin greater than 20% with respect to pre-treatment 
levels, were those with major changes in amino acid levels 
and Fischer ratio. No significant changes in the amino 
acid profile was induced by albumin dialysis in the con-
trol group. 
Three patients died within less than 36 d after treat-
ment. The median hospital stay of  the ten patients was 
16 d, and half  of  the patients were still alive 6 mo after 
treatment. No differences in the markers of  severity of  
the disease and plasma renin activity were observed be-
tween patients surviving less or more than 6 mo. Over-
all, the three-, six- and twelve-month survival rate were 
60%, 50% and 40%, respectively (Figure 3), results which 
parallel those observed in different trials using similar or 
other therapeutic approaches. Certainly, Jalan et al[36] also 
reported that 50% of  the 8 patients with AH treated with 
MARS were still alive with good liver function 3 mo after 
treatment. More recently, in a series of  15 patients with 
severe AH it has been reported that MARS was safe and 
well tolerated. Moreover, MARS therapy improved the 
overall survival of  patients who failed standard treatment 
and in 13% of  the cases was useful as a bridge to liver 
transplantation[42].
The largest randomized trial using an extracorporeal 
artificial device in patients with acute-on-chronic liver 
failure, indicate that MARS therapy improves some sur-
rogate parameters of  organ dysfunction. Accordingly, 
MARS was associated with a decrease in serum bilirubin 
and serum creatinine, and with a clear amelioration of  
hepatic encephalopathy in a high proportion of  cases[43]. 
These features occurred particularly in patients treated by 
MARS plus standard treatment. Most of  the patients were 
alcoholics but with a high rate of  precipitating events 
such as severe infections and gastrointestinal bleeding, not 
resulting particularly from histologic demonstrated AH. 
Another relevant aspect highlighted in this trial was the 
difficulty of  distinguishing acute-on-chronic liver failure 
from chronic decompensated liver disease, two entities 
that have different natural history and prognosis. 
In another trial, extracorporeal liver support with 
FPSA did not increase the probability of  survival as 
compared with standard medical therapy in patients with 
decompensated cirrhosis, although serum bilirubin de-
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Figure 2  Tumor necrosis factor-a (TNF-a) levels before and after molecular 
adsorbent recirculating system treatment in patients with severe alcoholic 
hepatitis. Although no significant decrease was observed in the circulating TNF-a, 
the dialysate was enriched with this cytokine, thus indicating that albumin dialysis is 
able to remove some substances related to the pathogenesis of the disease. 
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Figure 3  Cumulated survivals of the ten patients with severe alcoholic 
hepatitis treated with 3 consecutive 7-h molecular adsorbent recirculating 
system sessions. Fifty percent of the patients were still alive 6 mo after treat-
ment, and 40 percent survived 20 mo.
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creased markedly in the FPSA group but not in the stan-
dard medical therapy group[44]. This trial included fewer 
alcoholic patients, and therefore the probability of  an AH 
was subsequently lower.
CONCLUSION
The results reported until now on the effects of  extra-
corporeal liver support in patients with decompensated 
liver disease are somewhat confusing with respect to the 
patients’ selection and the etiology and severity of  the 
disease. Thus, it is very hard to allocate a unique group 
with severe AH with or without cirrhosis. The favorable 
effects of  albumin dialysis in patients with severe AH 
suggest that the procedure used alone or in combina-
tion with pharmacological therapies may have a role in 
this clinical condition, but this should be proved in well 
designed controlled trials, particularly with respect to the 
improvement of  short- and long-term survival. This will 
be particularly relevant to offer an alternative therapy in 
these patients, thus being a potential bridge to recovery 
or to be listed for liver transplantation[45]. In this concern, 
a randomized, controlled phase 3 trial to assess safety and 
efficacy of  a bio-artificial liver therapy in patients with 
severe AH who have failed seven days of  steroid therapy, 
is ongoing (ClinicalTrials.gov Identifier: NCT01829347). 
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